How much does a box of brigatinib cost in 2024?

Brigatinib (Brigatinib) is a potent oral tyrosine kinase inhibitor (TKI) designed to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It was developed by Ariad Pharmaceuticals in the United States and later acquired by Takeda Pharmaceuticals. Brigatinib was approved by the U.S. Food and Drug Administration (FDA) in in 2017 for the treatment of patients who have received at least one otherALKPatients with disease progression after treatment with ALK inhibitors (such as crizotinib)ALKpositiveNSCLC.

Brigatinib is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically for about four to five thousand yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper generic drugs abroad are generic drugs. The cheaper generic drugs in Laos cost about a few hundred yuan, which are much cheaper than domestic ones, and the ingredients of the drugs are basically the same.

The mechanism of action of brigatinib is to inhibit the tyrosine kinase activity of ALK, thereby blocking the signaling pathway related to the ALK fusion gene. This mechanism can effectively inhibit the growth and proliferation of tumor cells and induce their apoptosis. Compared with the first-generation ALKinhibitor crizotinib, brigatinib (brigatinib) Mutants (such as L1196M and G1202R, etc.) have higher affinity and inhibitory ability. In addition,Brigatinib (Brigatinib)can also penetrate the blood-brain barrier, so it also shows significant therapeutic effects on patients with brain metastases.

Clinical trial results for brigatinib are impressive. In a phase III clinical trial called ALTA-1L) and objective response rate (ORR) are significantly better than crizotinib. The study showed that the median PFS for brigatinib was 24.0 months, compared with 11.0 months for crizotinib. This result demonstrates the efficacy and safety of brigatinib (brigatinib) in crizotinib-resistant patients.

Common side effects of brigatinib include nausea, diarrhea, headache, cough and fatigue, and most patients can tolerate these side effects. A small number of patients may develop more serious pulmonary side effects, such as interstitial lung disease, so patients' lung function needs to be closely monitored in the early stages of treatment. In addition, Brigatinib may also cause hypertension, bradycardia, pancreatitis, etc., and corresponding biological indicators need to be monitored regularly during use.